6 results on '"Truchan‐Graczyk, Matgorzata"'
Number of results to display per page
Search Results
2. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
- Author
-
Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Neoplasm, Residual ,MESH: Immunotherapy ,Chronic lymphocytic leukemia ,Gastroenterology ,MESH: Clinical Trials, Phase III as Topic ,0302 clinical medicine ,Bone Marrow ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,MESH: Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Aged ,education.field_of_study ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,MESH: Follow-Up Studies ,Prognosis ,3. Good health ,Fludarabine ,Survival Rate ,Leukemia ,MESH: Antineoplastic Combined Chemotherapy Protocols ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,MESH: Vidarabine ,MESH: Bone Marrow ,Female ,MESH: Rituximab ,Immunotherapy ,Rituximab ,MESH: Clinical Trials, Phase II as Topic ,Vidarabine ,medicine.drug ,medicine.medical_specialty ,Cyclophosphamide ,MESH: Survival Rate ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH: Prognosis ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,Chemoimmunotherapy ,Internal medicine ,medicine ,Humans ,education ,Survival rate ,MESH: Neoplasm, Residual ,Aged ,Retrospective Studies ,MESH: Humans ,business.industry ,MESH: Cyclophosphamide ,MESH: Retrospective Studies ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Male ,body regions ,030104 developmental biology ,Clinical Trials, Phase III as Topic ,Bone marrow ,business ,MESH: Female ,Follow-Up Studies - Abstract
International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD
- Published
- 2020
3. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
- Author
-
Cottin, Laurane, primary, Riou, Jérémie, additional, Orvain, Corentin, additional, Ianotto, Jean Christophe, additional, Boyer, Françoise, additional, Renard, Maxime, additional, Truchan‐Graczyk, Matgorzata, additional, Murati, Anne, additional, Jouanneau‐Courville, Rébecca, additional, Allangba, Olivier, additional, Mansier, Olivier, additional, Burroni, Barbara, additional, Rousselet, Marie-Christine, additional, Quintin‐Roué, Isabelle, additional, Martin, Antoine, additional, Sadot‐Lebouvier, Sophie, additional, Delneste, Yves, additional, Chrétien, Jean‐Marie, additional, Hunault‐Berger, Mathilde, additional, Blanchet, Odile, additional, Lippert, Eric, additional, Ugo, Valérie, additional, and Luque Paz, Damien, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
- Author
-
Cottin, Laurane, Riou, Jérémie, Orvain, Corentin, Ianotto, Jean Christophe, Boyer, Françoise, Renard, Maxime, Truchan‐Graczyk, Matgorzata, Murati, Anne, Jouanneau‐Courville, Rébecca, Allangba, Olivier, Mansier, Olivier, Burroni, Barbara, Rousselet, Marie-Christine, Quintin‐Roué, Isabelle, Martin, Antoine, Sadot‐Lebouvier, Sophie, Delneste, Yves, Chrétien, Jean‐Marie, Hunault‐Berger, Mathilde, and Blanchet, Odile
- Subjects
DISEASE progression ,ALLELES ,MYELOFIBROSIS ,NUCLEOTIDE sequencing ,TUMORS ,BONE marrow - Abstract
Summary: In myeloproliferative neoplasms (MPN), JAK2V617F allele burden measurement has an impact on prognosis that helps in patient monitoring. Less is known about its usefulness in CALR‐mutated cases. Additional mutations found by next‐generation sequencing have also shown an impact on prognosis that may drive therapeutic choices, especially in myelofibrosis, but few studies focused on CALR‐mutated patients. We performed a molecular evaluation combining next‐generation sequencing with a myeloid panel and CALR allele burden measurement at diagnosis and during follow‐up in a cohort of 45 patients with CALR‐mutated essential thrombocythaemia. The bone marrow histology was also blindly reviewed in order to apply the WHO2016 classification. The most frequently mutated gene was TET2 (11/21 mutations). CALR type 1‐like patients appear to have a more complex molecular landscape. We found an association between disease progression and CALR allele burden increase during follow‐up, independently of additional mutations and WHO2016‐reviewed diagnosis. Patients with disease progression at the time of follow‐up showed a significant increase in CALR allele burden (+16·7%, P = 0·005) whereas patients without disease progression had a stable allele burden (+3·7%, P = 0·194). This result argues for clinical interest in CALR allele burden monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Normal levels of peripheral CD19+CD5+ CLL-like cells: Toward a defined threshold for CLL follow-up-A GEIL-GOELAMS study
- Author
-
Durrieu, Françoise, primary, Geneviève, Franck, additional, Arnoulet, Christine, additional, Brumpt, Caren, additional, Capiod, Jean-Claude, additional, Degenne, Michel, additional, Feuillard, Jean, additional, Garand, Richard, additional, Kara-Terki, Amina, additional, Kulhein, Emilienne, additional, Maynadié, Marc, additional, Ochoa-Noguera, Maria-Elena, additional, Plesa, Adriana, additional, Roussel, Mikael, additional, Eghbali, Houchingue, additional, Truchan-Graczyk, Matgorzata, additional, de Carvalho Bittencourt, Marcelo, additional, Feugier, Pierre, additional, and Béné, Marie C., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
- Author
-
Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, and Béné MC
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD19 blood, Antigens, CD19 immunology, CD5 Antigens blood, CD5 Antigens immunology, Cyclophosphamide therapeutic use, Female, Flow Cytometry, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell blood, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Lymphocyte Count, Male, Middle Aged, Neoplasm, Residual blood, Neoplasm, Residual immunology, ROC Curve, Reference Values, Sensitivity and Specificity, Vidarabine analogs & derivatives, Vidarabine therapeutic use, B-Lymphocytes chemistry, Immunophenotyping standards, Neoplasm, Residual diagnosis
- Abstract
Background: The development of flow cytometry as a useful tool for the detection of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is potentially hampered by the fact that a normal subset of B-cells with a similar immunophenotype is present in the peripheral blood. This subset of CLL-like cells is not well defined in terms of frequency., Methods: Here, we performed a multicenter study with a panel of four-color antibody combinations possibly useful for the detection of MRD in CLL, to establish the levels of normal CLL-like cells in 49 healthy controls. ROC curves established the upper level of such cells at 4 × 10(-4) . The two best combinations were further applied to 419 samples from 117 treated CLL patients., Results: The combinations CD19/CD5/CD43/CD79b and CD19/CD5/CD81/CD22 appeared very robust and well correlated to enumerate normal CLL-like cells in a lysis no-wash approach. In follow-up samples from CLL patients, they disclosed only 9.8% of the samples within the normal range. In more than 90% of the cases, it was thus possible to report confidently on the absence or presence of MRD in these patients., Conclusions: This manuscript reports on the frequency of CD19(+) CD5(+) B-cells in normal peripheral blood and confirms the combinations recommended by the European research initiative on CLL as being performing to assess remaining CLL cells above a threshold of 4 × 10(-4) white blood cells., (2011 International Clinical Cytometry Society.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.